# Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

> **NCT01380093** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 80 (actual)

## Conditions studied

- Nondependent Opioid Abuse, Episodic

## Interventions

- **DRUG:** Placebo
- **DRUG:** MS Contin (morphine sulfate, controlled release)
- **DRUG:** EMBEDA (morphine sulfate / naltrexone hydrochloride)

## Key facts

- **NCT ID:** NCT01380093
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2012-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380093, "Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01380093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*